A recent clinical study found that the FMD regimen reduced median plasma glucose concentration by 18.6% (range: -63.1% to +67.8%) and serum insulin by 50.7% (range: -91.3% to +697%). Data showed that associated weight loss was largely reversible during the healthy-eating intervals between FMD cycles. FMD-induced metabolic changes were independent of primary tumor type, concomitant anticancer treatments, and tumor stage. In contrast to previous studies, the compliance rate was 91.8% over all FMD cycles, meaning that nearly all patients were able to follow the FMD regimen.
The trial found the incidence of severe grade 3 or 4 FMD-related adverse events occurred at a rate of 12.9%, much lower than the prespecified 20% threshold. Although interleukin 6 (IL-6) plays an important role in the pathogenesis of cachexia and FMD-induced upregulation of the IL-6–SOCS3–LIF signature at the tumor level may be concerning, in this study, the FMD reduced blood IL-6 rather than increasing it, and patients maintained weight stably over subsequent FMD cycles.
Take another quiz on recent diet and nutrition studies.
This Rapid Review Quiz was excerpted and adapted from the Medscape articles: Intermittent Fasting Good for Weight Loss, At Least Short Term, Obesity, Intermittent Fasting Works, At Least in the Short Term, Parenteral and Enteral Nutrition, Cyclic Fasting Helps in Cancer Patients, Early Results Show, Skipping Breakfast Is Associated With an Increased Long-term Cardiovascular Mortality in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) but Not MAFLD-free Individuals, Fatty Liver Disease, Changes in Migraine Characteristics Over 30 Days of Ramadan Fasting, and Migraine Headaches.
Lead image: Everydayplus/Dreamstime
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Rapid Review Quiz: Intermittent Fasting - Medscape - May 06, 2022.